Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs

Private Biotech Raised $137m In Venture Capital In July

 
• By Mandy Jackson
White jigsaw puzzle on blue background
Merck & Co. added assets to its oncology pipeline with the VelosBios buy • Source: Shutterstock

More from Deals

More from Business